David Durantel
Overview
Explore the profile of David Durantel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
3699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Durantel D
Antiviral Res
. 2023 Jan;
210:105515.
PMID: 36603773
As a tribute to Dr Mike Bray, the following review of literature willbe mainly based on published data andconcepts, but will also contain my personal views, and in this respect...
12.
Bach C, Lucifora J, Delphin M, Heydmann L, Heuschkel M, Pons C, et al.
Antiviral Res
. 2022 Dec;
209:105477.
PMID: 36511319
Chronic hepatitis D is the most aggressive form of chronic viral hepatitis. It is caused by super-infection of hepatitis B virus (HBV)-infected hepatocytes with hepatitis D virus (HDV). While the...
13.
Lamrayah M, Charriaud F, Desmares M, Coiffier C, Megy S, Colomb E, et al.
Antiviral Res
. 2022 Dec;
209:105483.
PMID: 36496142
Hepatitis B virus remains a major medical burden with more than 250 million chronically infected patients worldwide and 900,000 deaths each year, due to the disease progression towards severe complications...
14.
Brancale A, Carter K, Delang L, Deval J, Durantel D, Gentry B, et al.
Antivir Chem Chemother
. 2022 Oct;
30:20402066221130853.
PMID: 36305015
As a result of the multiple gathering and travels restrictions during the SARS-CoV-2 pandemic, the annual meeting of the International Society for Antiviral Research (ISAR), the International Conference on Antiviral...
15.
Desmares M, Delphin M, Chardes B, Pons C, Riedinger J, Michelet M, et al.
Antiviral Res
. 2022 Aug;
206:105386.
PMID: 35963549
Objectives: Pegylated-interferon-alpha (Peg-IFNα), an injectable innate immune protein, is still used to treat chronically HBV-infected patients, despite its poor tolerability. Peg-IFNα has the advantage over nucleos(t)ide analogues (NAs) to be...
16.
Michelet M, Alfaiate D, Chardes B, Pons C, Faure-Dupuy S, Engleitner T, et al.
JHEP Rep
. 2022 Feb;
4(3):100415.
PMID: 35141510
Background & Aims: HDV superinfection of chronically HBV-infected patients is the most aggressive form of chronic viral hepatitis, with an accelerated progression towards fibrosis/cirrhosis and increased risk of liver failure,...
17.
Delphin M, Faure-Dupuy S, Isorce N, Rivoire M, Salvetti A, Durantel D, et al.
Viruses
. 2022 Jan;
14(1).
PMID: 35062269
Co-infection with the hepatitis B virus and hepatitis delta virus (HDV) leads to the most aggressive form of viral hepatitis. Using in vitro infection models, we confirmed that IL-1β, a...
18.
Verrier E, Salvetti A, Pons C, Michelet M, Rivoire M, Baumert T, et al.
Antiviral Res
. 2022 Jan;
198:105250.
PMID: 35051490
Chronic hepatitis D is the most severe form of chronic viral hepatitis and to date, efficient therapeutic approaches against hepatitis D virus (HDV) are limited. Among the antiviral molecules currently...
19.
Faure-Dupuy S, Riedl T, Rolland M, Hizir Z, Reisinger F, Neuhaus K, et al.
JHEP Rep
. 2021 Oct;
3(6):100354.
PMID: 34704004
Background & Aims: Immune-mediated induction of cytidine deaminase APOBEC3B (A3B) expression leads to HBV covalently closed circular DNA (cccDNA) decay. Here, we aimed to decipher the signalling pathway(s) and regulatory...
20.
Delphin M, Desmares M, Schuehle S, Heikenwalder M, Durantel D, Faure-Dupuy S
Liver Int
. 2021 Sep;
41(11):2547-2559.
PMID: 34520597
In their never-ending quest towards persistence within their host, hepatitis viruses have developed numerous ways to counteract the liver innate immunity. This review highlights the different and common mechanisms employed...